🎉 M&A multiples are live!
Check it out!

Capricor Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Capricor Therapeutics and similar public comparables like Armata Pharmaceuticals, Pharming, and Vivoryon Therapeutics.

Capricor Therapeutics Overview

About Capricor Therapeutics

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.


Founded

2005

HQ

United States of America
Employees

160

Website

capricor.com

Financials

LTM Revenue $9.3M

LTM EBITDA -$80.9M

EV

$174M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Capricor Therapeutics Financials

Capricor Therapeutics has a last 12-month revenue (LTM) of $9.3M and a last 12-month EBITDA of -$80.9M.

In the most recent fiscal year, Capricor Therapeutics achieved revenue of $22.3M and an EBITDA of -$41.1M.

Capricor Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Capricor Therapeutics valuation multiples based on analyst estimates

Capricor Therapeutics P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $9.3M XXX $22.3M XXX XXX XXX
Gross Profit n/a XXX n/a XXX XXX XXX
Gross Margin n/a XXX n/a XXX XXX XXX
EBITDA -$80.9M XXX -$41.1M XXX XXX XXX
EBITDA Margin -866% XXX -185% XXX XXX XXX
EBIT -$80.7M XXX -$42.6M XXX XXX XXX
EBIT Margin -863% XXX -191% XXX XXX XXX
Net Profit -$77.5M XXX -$40.5M XXX XXX XXX
Net Margin -829% XXX -182% XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Capricor Therapeutics Stock Performance

As of August 27, 2025, Capricor Therapeutics's stock price is $6.

Capricor Therapeutics has current market cap of $296M, and EV of $174M.

See Capricor Therapeutics trading valuation data

Capricor Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$174M $296M XXX XXX XXX XXX $-1.79

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Capricor Therapeutics Valuation Multiples

As of August 27, 2025, Capricor Therapeutics has market cap of $296M and EV of $174M.

Capricor Therapeutics's trades at 7.8x EV/Revenue multiple, and -4.2x EV/EBITDA.

Equity research analysts estimate Capricor Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Capricor Therapeutics has a P/E ratio of -3.8x.

See valuation multiples for Capricor Therapeutics and 15K+ public comps

Capricor Therapeutics Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $296M XXX $296M XXX XXX XXX
EV (current) $174M XXX $174M XXX XXX XXX
EV/Revenue 18.6x XXX 7.8x XXX XXX XXX
EV/EBITDA -2.2x XXX -4.2x XXX XXX XXX
EV/EBIT -2.2x XXX -4.1x XXX XXX XXX
EV/Gross Profit n/a XXX n/a XXX XXX XXX
P/E -3.8x XXX -7.3x XXX XXX XXX
EV/FCF n/a XXX -4.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Capricor Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Capricor Therapeutics Margins & Growth Rates

Capricor Therapeutics's last 12 month revenue growth is 736%

Capricor Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.

Capricor Therapeutics's rule of 40 is 645% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Capricor Therapeutics's rule of X is 975% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Capricor Therapeutics and other 15K+ public comps

Capricor Therapeutics Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth 736% XXX 130% XXX XXX XXX
EBITDA Margin -866% XXX -185% XXX XXX XXX
EBITDA Growth -56% XXX n/a XXX XXX XXX
Rule of 40 645% XXX 552% XXX XXX XXX
Bessemer Rule of X XXX XXX 975% XXX XXX XXX
Revenue per Employee XXX XXX $0.1M XXX XXX XXX
Opex per Employee XXX XXX $0.4M XXX XXX XXX
S&M Expenses to Revenue XXX XXX n/a XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 224% XXX XXX XXX
Opex to Revenue XXX XXX 291% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Capricor Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Capricor Therapeutics M&A and Investment Activity

Capricor Therapeutics acquired  XXX companies to date.

Last acquisition by Capricor Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Capricor Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Capricor Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.

Start Free Trial

About Capricor Therapeutics

When was Capricor Therapeutics founded? Capricor Therapeutics was founded in 2005.
Where is Capricor Therapeutics headquartered? Capricor Therapeutics is headquartered in United States of America.
How many employees does Capricor Therapeutics have? As of today, Capricor Therapeutics has 160 employees.
Who is the CEO of Capricor Therapeutics? Capricor Therapeutics's CEO is Dr. Linda Marban, PhD.
Is Capricor Therapeutics publicy listed? Yes, Capricor Therapeutics is a public company listed on NAS.
What is the stock symbol of Capricor Therapeutics? Capricor Therapeutics trades under CAPR ticker.
When did Capricor Therapeutics go public? Capricor Therapeutics went public in 2002.
Who are competitors of Capricor Therapeutics? Similar companies to Capricor Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Capricor Therapeutics? Capricor Therapeutics's current market cap is $296M
What is the current revenue of Capricor Therapeutics? Capricor Therapeutics's last 12 months revenue is $9.3M.
What is the current revenue growth of Capricor Therapeutics? Capricor Therapeutics revenue growth (NTM/LTM) is 736%.
What is the current EV/Revenue multiple of Capricor Therapeutics? Current revenue multiple of Capricor Therapeutics is 18.6x.
Is Capricor Therapeutics profitable? Yes, Capricor Therapeutics is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Capricor Therapeutics? Capricor Therapeutics's last 12 months EBITDA is -$80.9M.
What is Capricor Therapeutics's EBITDA margin? Capricor Therapeutics's last 12 months EBITDA margin is -866%.
What is the current EV/EBITDA multiple of Capricor Therapeutics? Current EBITDA multiple of Capricor Therapeutics is -2.2x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.